Astro-Med, Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Astro-Med, Inc. (also referenced as Astronova, Inc. in metadata), covering the three and nine-month periods ended October 30, 2004. The company is a multi-national enterprise designing, developing, and manufacturing data acquisition, storage, and analysis products. Operations are organized into three segments: Test & Measurement (T&M), QuickLabel Systems (QLS), and Grass-Telefactor (G-T).
Key Financial Metrics
| Metric | Three Months Ended Oct 30, 2004 | Nine Months Ended Oct 30, 2004 |
|---|---|---|
| Net Sales | $13,246,011 | $41,478,310 |
| Gross Profit | $5,151,914 (38.8% margin) | $16,865,853 (40.6% margin) |
| Operating Income | $6,791 | $1,859,441 |
| Net Income | $52,446 | $2,253,195 |
| Diluted EPS | $0.01 | $0.39 |
| Cash & Equivalents | $6,080,350 | $6,080,350 (Balance Sheet) |
| Operating Cash Flow (9mo) | N/A | $2,079,158 |
| Total Debt | None reported | None reported |
Material Changes vs. Prior Period
- Revenue: Three-month sales declined 7.9% to $13.2M compared to $14.4M in the prior year. Nine-month sales were flat at $41.5M versus $41.6M.
- Profitability: Operating income for the quarter collapsed to $6,791 from $1.06M in the prior year, driven by a significant drop in the T&M segment and increased operating expenses. Nine-month operating income decreased 26% to $1.86M.
- Segment Performance:
- T&M: Sales down 24% (quarter) and 4% (nine-months) due to declining defense spending and delays in Everest Telemetry orders. The segment reported an operating loss of $276,000 for the quarter.
- QLS: Sales up 12% (quarter) and 15% (nine-months), driven by strong demand for color printer systems (4100Xe and 8100Xe models).
- G-T: Sales down 21% (quarter) and 18% (nine-months) due to seasonal delays in clinical purchases and lower Long-term Epilepsy Monitoring sales.
- Tax Impact: The nine-month period included a one-time non-cash tax benefit of $939,000 from the release of a valuation allowance on deferred tax assets, resulting in a net tax benefit of $199,000 for the period.
Outlook, Risks, and Management Commentary
Management attributes the flat nine-month sales to a mix of declining defense spending (T&M) and seasonal delays (G-T), offset by growth in the QLS segment. The company maintains a strong liquidity position with $13.6M in cash and securities available for sale. Capital expenditures for the nine months were $899,000.
Risks and Contingencies:
- Declining demand in test and measurement markets, specifically defense and aerospace.
- Competition in specialty printer, data acquisition, and neurophysiology industries.
- Impact of foreign currency exchange rates on international results.
- Ability to successfully integrate acquisitions and develop market acceptance for new QLS products.
Capital Actions: The company declared a 10% stock dividend in April 2004 and paid cash dividends of $0.12 per share for the nine-month period. The company repurchased 5,000 shares in the third quarter.
Investor Verification Checklist
- T&M Segment Turnaround: Verify the sustainability of the T&M segment given the shift from research to armaments in defense spending and the resulting operating loss.
- Tax Benefit Normalization: Confirm that future earnings projections exclude the one-time $939,000 non-cash tax benefit recorded in the first quarter.
- QLS Growth Drivers: Assess the long-term demand for the 4100Xe and 8100Xe printers driving the QLS segment's growth.
- Expense Management: Review the 4% increase in SG&A and 12% increase in R&D expenses to ensure they align with revenue generation.
- Stock Dividend Impact: Ensure EPS comparisons account for the 10% stock dividend issued in May 2004, which restated share counts.